| P/E (FY) | — | Sales (TTM) | $33.9M |
| Earnings (TTM) | -$393.6M | ROE | — |
| Net Margin | −1236.42% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −7.35% |
| Market Cap | $57.9M | Trading Days | 925 |
| 52W High | 21.34 |
| 52W Low | 2.62 |
| % Off High | −68.04% |
| YTD | −10.22% | 1Y | −29.43% |
| 3Y | −94.18% | Since incept. (ann.) | −59.98% |
| Ann. Volatility (1Y) | 117.07% | Ann. Volatility (3Y) | 120.60% |
| Sharpe (1Y) | 0.27 | Sharpe (3Y) | −0.19 |
| Max Drawdown (1Y) | −80.27% | Max Drawdown (3Y) | −98.19% |
| Beta (3Y, vs SPY) | 3.56 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRDF | Cardiff Oncology, Inc. | $55.9M | — |
| INKT | MiNK Therapeutics, Inc. | $52.5M | — |
| LONA | LeonaBio, Inc. | $65.5M | — |
| TIL | Instil Bio, Inc. | $49.4M | — |
| ATYR | aTYR PHARMA INC | $48.4M | — |
| ATRA | Atara Biotherapeutics, Inc. | $70.4M | 3.0 |
| MGX | Metagenomi Therapeutics, Inc. | $45.6M | — |
| INMB | Inmune Bio, Inc. | $45.5M | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $76.8M | 16.8 |
| KLRS | Kalaris Therapeutics, Inc. | $79.5M | — |
| ELUT | ELUTIA INC. | $42.0M | 1.1 |
| CGTX |
| COGNITION THERAPEUTICS INC |
| $82.7M |
| — |
